Mastocytosis: A rare case of anaphylaxis in paediatric age and literature review

Allergologia et Immunopathologia

Volumn 36, Issue 3, 2008, Pages 154-163

  Silva, Isabel ^a,c   Carvalho, S ^a   Pinto, P L ^a   Machado, S ^b   Rosado Pinto, J ^a  

^a HOSPITAL DONA ESTEFÂNIA   (Portugal)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c NONE   (Portugal)

Author keywords

Anaphylaxis; Childhood; Classification; Criteria; Diagnosis; Mast cell; Mastocytosis; Review

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BORTEZOMIB; CETIRIZINE; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DENILEUKIN DIFTITOX; DESATINIB; FLUCLOXACILLIN; GELDANAMYCIN; GEMTUZUMAB OZOGAMICIN; HEPARIN; HYDROXYZINE; HYMENOPTERA VENOM; IMATINIB; KETOTIFEN; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; PSORALEN; RAPAMYCIN;

AGE; ANAMNESIS; ANAPHYLAXIS; ASCITES; ATOPIC DERMATITIS; BONE PAIN; BULLOUS SKIN DISEASE; CASE REPORT; CHILDHOOD DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CRITERION VARIABLE; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG INDICATION; ERYTHEMA; FACE ERYTHEMA; FEMALE; FLUSHING; GENE MUTATION; GENETIC ASSOCIATION; HOSPITAL ADMISSION; HUMAN; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; LABORATORY TEST; LOW DRUG DOSE; MALABSORPTION; MASTOCYTOSIS; MEDICAL LITERATURE; NECK RASH; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PHARMACEUTICAL CARE; PHOTOCHEMOTHERAPY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRESCHOOL CHILD; PUVA; RECURRENT DISEASE; RESPIRATORY ARREST; RESPIRATORY DISTRESS; REVIEW; SKIN BIOPSY; SKIN DEFECT; STOMACH ULCER; SYMPTOM; SYMPTOMATOLOGY; SYNCOPE; SYSTEMIC DISEASE; TACHYCARDIA; TRUNK; URTICARIA; URTICARIA PIGMENTOSA;

EID: 48249147868     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13124722     Document Type: Review

References (65)

1. Nettleship E, Tay W. Rare forms of urticaria. Br Med J 1869;2:323-30.
2. Unna PG. Beitrage zur anatomie und pathogeneses der urticaria simplex und pigmentosa. Mschr Prakt Dermat Studien 1887,3H:1.
3. Ellis JM. Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol 1949;48:426-9.
4. Horny H-P, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007;74:121-132.
5. Castells M. Mastocytosis: classification, diagnosis and clinical presentation. Allergy Asthma Proc 2004;25:33-36.
6. Fernández AT, Campoamor LN, Mora LE, Zambrano AZ. Diagnóstico, tratamiento y clasificatión de la mastocitosis pediátrica. Estúdio de 172 casos. Actas Dermosifiliogr 1998;89:461-476.
7. Rosbotham JL, Malik NM, Syrris P, Jeffery S, Bedlow A, Gharraie S et al. Lack of c-kit mutation in familial urticaria pimentosa. Br J Dermatol 1999;140:849-852.
8. Golkar L, Bernhar JD. Mastocytosis. Lancet 1997;349:1379-1385.
9. Valent P, Sillaber C, Bettelheim P. The growth and differentiation of mast cells. Prog Growth Factor Res 1991;3:27-41.
10. Valent P, Akim C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R et al. Mastocytosis: Pathology, genetics, and current opinions for therapy. Leukemia and Lymphoma 2005;46(1):35-48.
11. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit + and expresses aminopeptidase N (CD13). Blood 1999;94: 2333-2342.
12. Valent P. The riddle of the mast cell: c-kit ligand as missing link? Immunol. Today 1994;15:111-114.
13. Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny H-P et al. Morpholologic properties of neplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25:529-36.
14. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H et al. Effects of T-helper 2-type cytokines, interleukin-3(IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 2005;86:3705-14.
15. Godfrain C, Louaed J, Faulkner H, Vink A, Warnier G, Grencis R et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea and kidneys of IL-9 transgenic mice. J Immunol 1998;160:3989-96.
16. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991;173:507-10.
17. Tagaya Y, Burton JD, Miyamoto Y, Waldmann TA. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. Embo J 1996;15:4928-39.
18. Valent P, Spanblöchl E, Sperr WR, Sillaber Ch, Agis H, Zsebo K et al. Induction of differentiation human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culter. Blood 1992;80:2237-45.
19. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor and mast cells. What each is teaching us about the others. Am J Pathol 1993;142:965-74.
20. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with especial reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol;127:110-14.
21. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Susuki Y. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated haematologic disorder. Proc Natl Acad Sci (USA) 1995;92:10560-64.
22. Longley BJ, Metcalf DD, Tharp M, Wang, Tyrrel L, Lu S-Z et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci (USA) 1999;96:1609-14.
23. Büttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutation in adult-, but not childhood -onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. J Invest Dermatol 1998;111:1227-31.
24. Yavuz AS, Lipsky PE, Yavus S, Metcalfe DD, Akin C. Evidence for the involvement of an hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutation in the c-kit gene. Blood 2002;100:661-65.
25. Ferrão PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakaryocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res 2003;27:547-55.
26. Swolin B, Rodjer S, Roupe G. Cytogenetic studies in patients with mastocytosis. Cancer Genet Cytogenet 2000;120:131-135.
27. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV et al. A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-78.
28. Valent P, Sperr WR, Schwart LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell haematopoietic neoplasms. J Allergy Clin Immunol 2004;114:3-11.
29. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577-584.
30. Yanagihori H, Oyama N, Nakamura K, Kaneko F. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005;7:252-7.
31. Schernthaner GH, Jordan JH, Ghannadan M, Agis H, Bevec D, Nuñez R et al. Expression, epitope analysis and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001;98:3784-92.
32. Escribano L, Díaz-Agustín B, Bellas C, Navalón R, Nuñez R, Sperr WR et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001;25:563-70.
33. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al. The Alfa form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-10.
34. Sperr WR, Jordan JH; Fiegl M, Escribano L, Dirnhofer S, Semper H et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128:136-141.
35. Azana JM, Torrelo A, Mediero IG, Zambrano A. Urticaria pigmentosa: a review of 67 paediatric cases. Ped Dermatol 1994;11:102-106.
36. Kettelhut BV, Metclf DD. Paediatric mastocytosis. Ann Allergy 1994;73:197-207.
37. Kettelhut BV, Metclf DD. Paediatric mastocytosis. J Invest Dermatol 1991;96:15-18S.
38. Hansen U, Wiese R, Knolle J. Schock and coagulation disorders in systemic mastocytosis. Dtsch Med Wochenscher 1994;119:1231-4.
39. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:579-623.
40. Campbell EW, Hector D, Gossin V. Heparin activity in systemic mastocytosis. Ann Int Med 1979;90:940-1.
41. Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
42. Hartmann K, Metcalf DD. Paediatric mastocytosis. Hematol Oncol Clin North Am 2000;14:625-40.
43. Shiloh-Malawsky Y, Confino Y, Yosipovitz A, Nassan D, Augarten A. Mastocytosis: The paediatric emergency physician's perspective. Pediatr Emerg Care 2003;19:172-3.
44. Carter MC, Metcalf DD. Paediatric mastocytosis. Arch Dis Child 2002;86:315-9.
45. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000;14:557.
46. Topar G, Staudacher C, Geisen F, Gabl C, Fend F, Herald M et al. Urticaria pigmentosa: a clinical hematopathologic and serologic study of 30 adults. Am J Clin Pathol 1998;109:279-85.
47. Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001;144:682-95.
48. Orkin M, Good RA, Clawson C, Fisher I, Windhorst D. Bullous mastocytosis. Arch Dermatol 1070;101:547-74.
49. Wolff K, Komar M, Petzelbauer P. Clinical and pathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:603-625.
50. Holly C, Shaffer BS, Daniel J et al. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a paediatric patient: Case report and literature review. J Am Acad Dermatol 2006;54:S210-3.
51. Akin C, Metcalfe DD. Systemic mastocytosis. Annu. Rev. Med. 2004;55:419-32.
52. Horny H-P, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria and immunohistochemical findings. Leuk Res 2001;25:543-551.
53. Valent P, Akim C, Sperr WR, Horny H-P, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:1-23.
54. Escribano L, Akim C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002;81:677-90.
55. Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980;303:1400-4.
56. Metcalfe DD. The treatment of mastocytosis. J Invest Dermatol 1991;96:64S.
57. Povoa P, Ducla-Soares J, Fernandes A, Palma Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991;229:475-7.
58. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymnoptera venom allergy. Current Opin Allergy Clin Imunol 2006;6(4):284-8.
59. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35-9.
60. Friedman B, Darling G, Norton J, Hamby L, Metcalfe DD. Splenectomy in management of systemic mast cell disease. Surgery 1990;107:94-100.
61. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-39.
62. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45.
63. Zermati Y, De Sepulveda P, Feger P, Letard S, Kersual J, Casteran N et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cells neoplasms. Oncogene 2003;22:660-4.
64. Tefferi A. Treatment of systemic mast cell disease: beyond interferon. Leuk Res 2004;28:223-4.
65. Siebenhaar F, Kühun W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120:213-5.